Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
 

Acute Myeloid Leukemia Clinical Trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (549) clinical trials

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS AML and CMML Patients

This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical study includes ...

Phase

Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

All subjects entering the screening phase will receive a unique subject number. This number will be used to identify the subject throughout the study. Additional test to include: physical examinations, blood tests, and if applicable pregnancy test will be performed as part of participation in this research study. Lenalidomide will ...

Phase

Extramedullary Leukemia (EML) in Newly Diagnosed Acute Myeloid Leukemia (AML) is Underreported

If you choose to take part in this study, you will have a PET/MRI and PET/CT scan before you start your regular treatment. When you arrive at the clinic for your PET/MRI-PET/CT scans, you will receive a "radioisotope" and a "contrast" solutions by vein to make the images more accurate. ...

Phase

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will evaluate the safety. tolerability and the pharmacokinetics of ABBV-075 monotherapy ...

Phase

An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (>65 Years) Patients

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Arm 1: Up to 5 groups of up to 6 participants will be enrolled in Part A of the study, ...

Phase

An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 5 groups of up to 6 participants will be enrolled in the lead-in phase of the study, and ...

Phase

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

There are two patient subgroups: 1) those who were in complete remission (CR) at the time of transplant, and 2) those who were not in complete remission (NCR) at the time of transplant. Start of crenolanib therapy at 100 mg TID is intended at the earliest time no sooner than ...

Phase

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

For each arm: The phase I with dose-limiting toxicity (DLT) determination will use 3+3 design. Phase II total of 52 patients (26 per arm) will be treated at established phase I dose. Enrollment to be simultaneous to each arm.

Phase

DC Vaccination for Post-remission Therapy in AML

This is a multi-centre, open label, prospective, non-randomized phase I/II trial in 20 patients including a safety-run in phase I part comprising 6 patients. Trial subjects will receive repeated immunotherapies with autologous Dendritic Cells (DCs), presenting two leukemia-associated antigens.

Phase

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation

Phase 1 (Safety Run-In): Following Screening, a total of up to 30 subjects in up to 5 dose cohorts will be enrolled to establish the RP2D. The safety run-in phase will be a standard 3+3 cohort design. Phase 2a (Expansion): Once the Phase 1 Safety Run-In portion of the study ...

Phase